India, Jan. 21 -- Sigachi Industries announced a significant milestone in its research and development pipeline with the successful advancement of a new Cystic Fibrosis (CF) Active Pharmaceutical Ingredients (APIs) combination comprising Vanzacaftor, Tezacaftor, and Deutivacaftor.The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments.The global cystic fibrosis therapeutics market is estimated to exceed USD 10 billion, driven by growing adoption of next-generation modulator therapies, long-term treatment requirements, and strong pricing resilience. Against this backdrop, Sigachi...